Wilmot Cancer Institute - University of Rochester

601 Elmwood Avenue
Rochester, New York 14642

We've found

1 trials

at this facility

Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL

Status: Enrolling, Phase I, II
Updated: 12/31/1969

from

Rochester, NY

Use our guide to learn which trials are right for you!